In Depth 26 Nov 2025 Beyond GLP-1s: is there a new wave of metabolic disease treatments? A new wave of metabolic disease treatments beyond GLP-1 agonists is emerging to address the unmet needs of patients. November 26, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2025 Six key obesity deals in 2025 Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies. November 21, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2025 Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring Discover how Novo Nordisk’s pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and obesity. November 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 Eight AI deals in 2025: Discover where industry leaders are betting big Artificial intelligence (AI) is rapidly transforming the biotechnology landscape, and as it does, we are seeing more and more strategic collaborations and partnerships focused on the technology. These partnerships make use of AI to analyze complex biological data, speed up drug discovery, and improve the design of clinical trials. By combining AI’s data-crunching capabilities with […] October 28, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 24 Sep 2025 Eli Lilly’s strategy in motion: Beyond diabetes and obesity Delve into a biopharma giant’s strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. September 24, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2025 GLP-1 drugs on WHO Essential Medicines List: what’s the impact? The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision. September 19, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Jun 2025 Did Novo open the Canadian market to GLP-1 generics? Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee? June 16, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 New weight loss drugs: Biotech’s mission to end obesity Find out more about biotech’s mission to end obesity, as we look at the new weight loss drugs that are in development. May 28, 2025 - 17 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2025 Top biotech deals of March 2025 Learn about the top biotech deals of March 2025. Small molecules, bispecific antibodies, and protein therapies were all part of major collaborations. April 2, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Mar 2025 Can GLP-1 agonists help treat addiction? Discover how researchers have been exploring the potential of GLP-1 drugs for treating addiction disorders. March 14, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 21 Feb 2025Can RNA drugs solve the obesity epidemic? This week, we have a conversation with Alessandro Toniolo, CEO of Resalis Therapeutics, about a non-coding RNA drug candidate that promotes sustainable weight loss. February 21, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 7 Feb 2025Targeting the dark genome to develop new therapies to fight obesity This week, our podcast guest is Samir Ounzain, CEO of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’ February 7, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More